The consistent upregulation of Hsp70s following Hsp90 and proteasome inhibition, and their proven anti-apoptotic roles contributing to drug resistance leads to a growing interest in the development of Hsp70 inhibitors to be used as single anti-cancer agents or in combination with conventional or targeted chemotherapies. This evidence concerns the gene HSP90AA1 and cancer.